TPO Antibodies: What This Test Means for Women and Which Drugs Distort the Results

What TPO Antibodies Actually Measure

Thyroid peroxidase (TPO) is the enzyme your thyroid uses to oxidize iodide and attach it to thyroglobulin, a step without which your thyroid cannot synthesize T3 or T4. When your immune system misidentifies TPO as a foreign threat, it produces TPO antibodies (TPO Ab, also written anti-TPO). These antibodies are the biochemical fingerprint of autoimmune thyroid disease.

A positive result tells your clinician your immune system is attacking your own thyroid tissue. It does not, on its own, tell them how much thyroid function you have lost. That is why TPO Ab is always read alongside TSH and free T4, not in isolation.

Why Women Are Disproportionately Affected

Autoimmune thyroid disease is seven to ten times more common in women than in men. The reasons are incompletely understood, but sex hormones, X-chromosome gene dosage, and fetal microchimerism (fetal cells that linger in maternal tissue for decades) all appear to lower the threshold for thyroid autoimmunity. Estrogen receptors on immune cells modulate B-cell activity; as estrogen fluctuates across the menstrual cycle, the intensity of antibody production can shift with it.

A useful framework for reading a woman's TPO Ab result accounts for four hormonal contexts: reproductive years with regular cycles, the trying-to-conceive and pregnant state, the postpartum window, and perimenopause or post-menopause. Each context changes what the number means clinically.

What the Number Does and Does Not Tell You

A high TPO Ab titer confirms autoimmunity. It does not predict how quickly, or whether, overt hypothyroidism will develop. In the NHANES III data, roughly 13% of adults with positive TPO antibodies had a TSH above 4.5 mIU/L at the time of testing, meaning the majority were still euthyroid. Serial titers over months to years trend downward in some women without any intervention, and trend upward in others despite treatment.

Normal TPO Antibody Range for Women

Most commercial immunoassay platforms report a negative result as <35 IU/mL, though the exact cut-off varies by laboratory method. Quest Diagnostics and LabCorp both use <34 or <35 IU/mL as their upper reference limit. Results between 35 and 100 IU/mL are sometimes called borderline or weakly positive; results above 100 IU/mL are considered clearly elevated.

Reference Ranges Across Life Stages

Reference ranges were largely derived from populations that included postmenopausal women, and age affects baseline positivity rates:

• Reproductive-age women (18-44): Prevalence of TPO positivity is approximately 8-14%
• Perimenopausal women (45-55): Prevalence rises; subclinical hypothyroidism affects up to 20% of women in this age bracket, much of it autoimmune in origin
• Post-menopausal women (>55): TPO Ab positivity rates approach 15-18% in some population studies

The AACE and American Thyroid Association do not endorse routine population screening for TPO antibodies in asymptomatic adults. Testing is recommended when TSH is abnormal, when symptoms suggest thyroid dysfunction, or in the setting of pregnancy planning and fertility evaluation.

When a "Normal" Result Can Still Be Meaningful

A result of 28 IU/mL looks negative by the reference range. However, if your TSH is creeping above 2.5 mIU/L and you have classic Hashimoto's symptoms (fatigue, cold intolerance, hair loss, constipation), a near-threshold TPO Ab combined with thyroid ultrasound findings can still lead to a diagnosis. The test is one data point, not a verdict.

Drugs and Supplements That Distort TPO Antibody Results

This section is the clinical core of this article. Several medications and supplements alter either the immune response driving antibody production, or the assay chemistry used to detect the antibodies. Understanding the difference matters for timing your test.

Drugs That Interfere with the Assay Chemistry

These agents change what the immunoassay reads, not what your immune system is actually doing.

Biotin (Vitamin B7) Biotin is the most clinically significant non-drug interferent for thyroid immunoassays. Many immunoassay platforms use a biotin-streptavidin capture system. High-dose biotin, commonly taken in doses of 5,000-10,000 mcg/day for hair growth or neurological conditions, saturates the streptavidin sites and produces falsely low TPO Ab results. The FDA issued a safety communication on this in 2017 and updated it in 2019. The standard recommendation is to stop biotin supplementation for at least 72 hours before any immunoassay-based thyroid panel.

Heterophile Antibodies Some women have circulating heterophile antibodies, proteins that cross-react with the animal antibodies used in immunoassays. These are not from any drug but can be triggered or amplified by certain biologic therapies. Heterophile antibody interference can produce falsely elevated or falsely low TPO Ab, depending on the assay format.

Drugs That Alter Immune Activity and May Genuinely Change TPO Ab Titers

These agents modify the autoimmune process itself, which means they change the biology, not just the readout.

Selenium Selenium supplementation at 200 mcg/day for 12 months reduced TPO Ab titers by approximately 49% in a randomized trial by Gärtner et al., published in the Journal of Clinical Endocrinology and Metabolism in 2002. A subsequent Cochrane-level review suggested the effect on TPO Ab titers is consistent, though the clinical benefit in terms of reduced progression to overt hypothyroidism remains debated. If a patient is supplementing selenium before testing, the titer may be genuinely lower, reflecting a reduced immune burden rather than an assay artifact.

Glucocorticoids (Prednisone, Dexamethasone) Systemic corticosteroids are immunosuppressants. A course of prednisone at doses of 20-40 mg/day, as commonly used for asthma or autoimmune flares, may transiently suppress TPO Ab titers by dampening overall B-cell activity. Testing during or immediately after a course of oral steroids can underestimate your baseline titer.

Checkpoint Inhibitor Immunotherapies (Pembrolizumab, Nivolumab, Atezolizumab) PD-1 and PD-L1 inhibitors used in cancer treatment are increasingly recognized as causes of immune-related adverse events, including de novo thyroid autoimmunity. Thyroiditis with elevated TPO antibodies has been reported in 5-10% of patients on pembrolizumab. If you are on or recently completed checkpoint inhibitor therapy, a newly elevated TPO Ab reflects a drug-induced immune activation, not a pre-existing Hashimoto's pattern.

Lithium Lithium inhibits thyroid hormone secretion and has been associated with both goiter and thyroiditis. Lithium-induced thyroiditis can be accompanied by elevated TPO Ab, particularly in women with pre-existing subclinical autoimmunity who might not have developed overt Hashimoto's without the lithium exposure. Women on long-term lithium for bipolar disorder should have thyroid antibodies checked at baseline and annually.

Amiodarone Amiodarone is 37% iodine by weight and disrupts thyroid function through multiple mechanisms. It can trigger both hypothyroidism and hyperthyroidism. In the context of TPO Ab, amiodarone-induced thyroid inflammation may raise titers, particularly in iodine-sufficient women with pre-existing subclinical autoimmunity. Interpreting a TPO Ab result in a woman on amiodarone requires knowing her antibody status before starting the drug.

Interferon-Alpha Used historically for hepatitis C and still used in some oncology and autoimmune protocols, interferon-alpha is a potent inducer of thyroid autoimmunity. Up to 40% of women treated with interferon-alpha develop thyroid antibodies, and a significant subset progress to clinical hypothyroidism. This is a genuine induction of autoimmunity, not an assay artifact.

Tyrosine Kinase Inhibitors (Sunitinib, Sorafenib) These targeted cancer therapies are associated with thyroid dysfunction, and some reports document elevated TPO Ab in women who were antibody-negative before treatment. The mechanism may involve drug-induced destructive thyroiditis releasing thyroid antigens and triggering an immune response.

Hormonal Drugs and Their Relationship to TPO Ab

Oral Contraceptives and Estrogen-Containing Therapies Estrogen modulates immune function. Women on combined oral contraceptives (COCs) tend to have slightly higher immunoglobulin levels. There is no strong evidence that COCs meaningfully change TPO Ab titers in most women, but the immunomodulatory effect of estrogen withdrawal (as seen when stopping COCs or entering perimenopause) can unmask subclinical thyroid autoimmunity. A new positive TPO Ab result shortly after stopping estrogen-containing therapy should be interpreted with this context in mind.

Levothyroxine Levothyroxine itself does not suppress TPO antibodies. It replaces the missing thyroid hormone but does not address the underlying autoimmune process. Some studies suggest that achieving a low-normal TSH with levothyroxine may modestly lower antibody titers over years, but the evidence is inconsistent.

TPO Antibodies Across Women's Life Stages

Reproductive Years and the Menstrual Cycle

Thyroid hormone requirements increase in the luteal phase, and some women with subclinical autoimmune thyroiditis notice symptom fluctuations that track their cycles. TPO Ab titers themselves do not reliably shift with the cycle, but a borderline result drawn at different cycle phases by the same lab may show small numerical variation.

Trying to Conceive and Early Pregnancy

This is where TPO Ab status carries its clearest clinical weight. ACOG and ASRM both recognize euthyroid TPO Ab positivity as a risk factor for miscarriage and recurrent pregnancy loss. Women with positive TPO antibodies and a TSH above 2.5 mIU/L who are attempting to conceive may be started on low-dose levothyroxine based on American Thyroid Association guidance, though this practice is not universally endorsed.

A 2019 randomized trial published in the New England Journal of Medicine found that levothyroxine did not improve live birth rates in euthyroid women with positive TPO antibodies and a history of pregnancy loss, which challenged earlier practice. The debate continues; the current pragmatic approach at most reproductive endocrinology centers is to maintain TSH below 2.5 mIU/L in TPO-positive women during active conception attempts.

Pregnancy

Thyroid hormone requirements increase by approximately 30-50% during pregnancy due to rising TBG, placental deiodinase activity, and fetal thyroid demands. TPO-positive pregnant women need more frequent TSH monitoring (every 4 weeks in the first trimester, then every 4-6 weeks thereafter) compared to antibody-negative women. Gestational thyroiditis, distinct from Hashimoto's, can cause transient hypothyroidism during pregnancy.

Pregnancy Safety of Drugs That Affect TPO Ab: Selenium supplementation during pregnancy has been studied in the context of reducing postpartum thyroiditis risk. A trial published in Thyroid in 2007 (Negro et al.) found that selenium 200 mcg/day from the first trimester through 12 months postpartum reduced postpartum thyroiditis rates and permanent hypothyroidism in TPO-positive women. Selenium at nutritional doses (up to 200 mcg/day) is considered compatible with pregnancy, though doses above 400 mcg/day carry teratogenic risk. Glucocorticoids, when medically necessary during pregnancy, are generally used at the lowest effective dose; they are not used to manage TPO Ab titers in pregnancy.

Checkpoint inhibitors are contraindicated in pregnancy. Women of reproductive age on pembrolizumab or nivolumab must use effective contraception; both drugs can cause fetal harm based on mechanism.

Postpartum and Lactation

Postpartum thyroiditis affects 5-7% of all women within the first year after delivery; in TPO-positive women, the risk rises to 33-50%. The classic pattern is a hyperthyroid phase at 1-4 months postpartum, followed by a hypothyroid phase at 4-8 months, with most women recovering euthyroid status by 12 months. However, 20-40% develop permanent hypothyroidism within 5-10 years.

During lactation, levothyroxine is safe. Selenium at nutritional doses is safe in breastfeeding. Checkpoint inhibitors are contraindicated during breastfeeding due to unknown transfer and potential infant immunosuppression.

Perimenopause and Post-Menopause

Perimenopause brings erratic estrogen fluctuations that can unmask or worsen thyroid autoimmunity. Symptoms overlap substantially: fatigue, weight gain, mood changes, disrupted sleep, irregular cycles. A TPO Ab level combined with TSH should be part of any perimenopause workup that presents with overlapping symptoms, because starting menopausal hormone therapy (MHT) in a woman who actually has undertreated hypothyroidism will not relieve her symptoms adequately.

Post-menopausal women on MHT may need slightly higher levothyroxine doses if already on thyroid replacement, because oral estrogen increases TBG and reduces free T4 availability. This interaction is well-documented in the literature and warrants a TSH recheck 6-8 weeks after starting oral MHT.

How to Lower TPO Antibodies: What the Evidence Actually Supports

The evidence base here is narrower than many online sources suggest. Three interventions have controlled trial data:

Selenium 200 mcg/day: The most replicated finding. The Gärtner 2002 trial and the Negro 2007 trial both showed significant titer reductions and, in the postpartum study, reduced clinical outcomes. The effect size is meaningful: roughly 40-50% reduction in titers over 6-12 months.

Gluten-free diet in women with concurrent celiac disease: Celiac disease co-occurs with Hashimoto's at rates approximately 3-5 times higher than in the general population. In women who have both conditions, strict gluten exclusion may reduce TPO Ab titers, presumably by reducing intestinal inflammation and molecular mimicry. There is no evidence that a gluten-free diet reduces TPO Ab in women without celiac disease or documented non-celiac gluten sensitivity.

Vitamin D repletion: Low vitamin D is associated with higher TPO Ab titers in observational data. A 2017 meta-analysis in Hormones found that vitamin D supplementation reduced TPO Ab in women with Hashimoto's and documented deficiency. The effect appears to require correcting actual deficiency (25-OH vitamin D below 20 ng/mL) rather than supplementing in replete women.

What is not supported by controlled trial data: strict iodine restriction (unless in the setting of excess iodine intake), low-dose naltrexone (case reports only), and most elimination diets beyond the celiac exception.

Who Should Be Tested for TPO Antibodies

Testing is appropriate, not routine screening for all. Consider it when:

• TSH is elevated (above 4.5 mIU/L) or suppressed without an obvious cause
• You have symptoms consistent with Hashimoto's: fatigue, weight gain, hair thinning, constipation, cold intolerance, brain fog, heavy or irregular periods
• You are planning a pregnancy or experiencing recurrent miscarriage
• You are in perimenopause with symptoms that do not fit neatly into an estrogen-deficiency pattern
• You have another autoimmune condition (type 1 diabetes, celiac disease, rheumatoid arthritis, lupus), since thyroid autoimmunity clusters with other autoimmune diseases
• You are on lithium, interferon-alpha, amiodarone, or a checkpoint inhibitor

Testing is not indicated simply because you take a supplement that might lower titers, or because a relative has Hashimoto's with no personal symptoms or TSH abnormality.

Who This Is Right for and Who It Is Not

A TPO Ab test is likely the right next step if you are a woman with an elevated TSH of uncertain cause, a history of pregnancy loss, symptoms overlapping with thyroid dysfunction in the context of a normal TSH (which may prompt further nuance in interpretation), or planned fertility treatment.

A TPO Ab test adds less value if your TSH is consistently normal, you have no autoimmune history, and you have a clear alternative explanation for your symptoms. A positive result in this context can cause anxiety without providing an actionable clinical path, since euthyroid TPO Ab positivity in the absence of symptoms or TSH abnormality does not have a proven treatment that changes outcomes in non-pregnant women.

Life-stage specifics:

• Trying to conceive: test, because the result changes TSH targets and monitoring intensity
• First trimester: if not tested before conception, test at the first prenatal visit
• Postpartum: test at 6-8 weeks postpartum if you are TPO-positive, or if you develop symptoms of thyroiditis; recheck at 3-4 months and 6 months
• Perimenopause: test if TSH is above 3.0 mIU/L or if the symptom burden does not fit a purely hormonal picture
• Post-menopause: test if starting levothyroxine for newly identified hypothyroidism, to establish whether it is autoimmune or another etiology